Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Akebia Therapeutics (AKBA) Stock Price & Analysis
1,202 Followers
AKBA Stock Chart & Stats
Day’s Range$1.31 - $1.35
52-Week Range― - ―
Previous Close$1.37
Volume2.56M
Average Volume (3M)N/A
Market Cap
$286.84M
Enterprise Value$287.55M
Total Cash (Recent Filing)$42.92M
Total Debt (Recent Filing)$43.63M
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 06, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding209,372,275
10 Day Avg. Volume2,937,372
30 Day Avg. Volume7,514,564
Standard Deviation0.31
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.28
Price to Sales (P/S)1.47
Price to Cash Flow (P/CF)-31.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-40.00
Forecast
1Y Price Target
$5.00Price Target Upside275.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Akebia Therapeutics News
PremiumCompany Announcements
Akebia Therapeutics Celebrates FDA Approval of Anemia Drug
PremiumCompany Announcements
Akebia Therapeutics Announces CFO Transition and Interim PlanBulls Say, Bears Say
Bulls Say
Competitive AdvantageThe Vafseo label includes a simple dosing regimen and does not carry a warning for 'risk of hospitalization for heart failure' unlike its competitor, providing a potential advantage.
Financial StrengthBalance Sheet Strengthened With New $55M loan from BlackRock, enhancing funding optionality for operating plan.
Regulatory ApprovalFDA approves Vafseo for anemia in CKD on dialysis, marking a significant regulatory milestone.
Bears Say
FDA Approval RisksRisks include potential failure to secure FDA approval for vadadustat in dialysis.
Market And Competition ChallengesChallenges may arise from market size, competition, pricing, or intellectual property opposition.
Regulatory ConcernsVafseo's label comes with black box warnings, which are standard for drugs in its class but may affect its perception among prescribers and patients.
---
Ownership Overview
5.55% Insiders
8.59% Mutual Funds
4.50% Other Institutional Investors
81.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 10 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Mar 14, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.038.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -$0.07.
How many shares outstanding does Akebia Therapeutics have?
Currently, no data Available
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went up 24.088%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 29K.
---
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (275.94% Upside)
$5.00 (275.94% Upside)
Blogger Sentiment
Bullish
AKBA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 23.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $300.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.12%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AKBA Earnings Call
Q3 2023
0:00 / 0:00
---
AKBA Stock 12 Months Forecast
Average Price Target
$5.00
▲(275.94% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Corbus Pharmaceuticals
―
Karyopharm Therapeutics
―
Xencor
―
Best Analysts Covering AKBA
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-23.11%
reiterated a buy rating 25 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -23.11% per trade.
---